<div id="readability-page-1">Ventyx Biosciences Inc. (NASDAQ:VTYX) is among the hottest SMID-cap stocks so far in 2025. On November 7, TheFly reported that Canaccord Genuity modestly increased its price target on the company’s stock from $14 to $16 while reiterating a Buy rating following the company’s Q3 results report a day earlier. Canaccord is now factoring in lower operating […]</div>

VTYX

<p>Canaccord Genuity 將 Ventyx Biosciences (NASDAQ:VTYX) 的目標股價從 14 美元上調至 16 美元，並在公司第三季度業績發佈後維持 “買入” 評級。該股票被認為是 2025 年最熱門的中小型股之一，前景因成本優化和積極的臨牀數據而得到增強</p>

Ventyx Biosciences (VTYX) 的前景因成本優化和積極的臨牀數據而更加樂觀